Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its
increasing global prevalence and because chronic hyperglycemic states are closely linked …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Diabetes mellitus is a chronic multifaceted disease with multiple potential complications, the
treatment of which can only delay and prolong the terminal stage of the disease, ie, type 2 …

This study aimed to better understand the beneficial effect of oat phenolic compounds (OPC)
in improving metabolic syndrome via regulating metabolites and gut microbiota composition …

Diabetes mellitus is a group of metabolic disorders characterized by hyperglycemia caused
by resistance to insulin action, inadequate insulin secretion, or excessive glucagon …

Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires
polypharmacological treatment of the single conditions including type II diabetes …

In 2022, 23 new small molecule chemical entities were approved as drugs by the United
States FDA, European Union EMA, Japan PMDA, and China NMPA. This review describes …

Background Epidemiological studies on the associations of legacy per-and polyfluoroalkyl
substances (PFASs) and glucose homeostasis remain discordant. Understanding of PFAS …

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, affected by
both genetics and environment. Type 2 diabetes (T2D) stands as an independent …

The current research and existing facts indicate that type 2 diabetes mellitus (T2DM) is
characterized by gut microbiota dysbiosis and disturbed microbial metabolites. Oral glucose …